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Abstract
Fluorescent and luminescent probes are essential to both in vitro molecular assays and in vivo imaging techniques, and have
been extensively used to measure biological function. However, little is known about the biological activity, thus potential
interferences with the assay results, of these probe molecules. Here we show that D-luciferin, one of the most widely used
bioluminescence substrates, is a partial agonist for G protein-coupled receptor-35 (GPR35). Label-free phenotypic profiling
using dynamic mass redistribution (DMR) assays showed that D-luciferin led to a DMR signal in native HT-29 cells, whose
characteristics are similar to those induced by known GPR35 agonists including zaprinast and pamoic acid. DMR assays
further showed that D-luciferin is a partial agonist competitive to several known GPR35 agonists and antagonists. D-luciferin
was found to cause the phosphorylation of ERK that was suppressed by known GPR35 antagonists, and also result in b-
arrestin translocation signal but with low efficacy. These results not only suggest that D-luciferin is a partial agonist of
GPR35, but also will evoke careful interpretation of biological data obtained using molecular and in vivo imaging assays
when these probe molecules are used.
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Introduction
With the advances in detection technology have expanded the
applications of fluorescent and luminescent probe molecules for
measuring a myriad of biological functions [1]. However, these
probe molecules could introduce assay artifacts and alter
performance or functions of proteins and cells. Further, dominated
in the target-centric basic research and drug discovery are
molecular assays that measure a specific signaling pathway and/
or molecule to infer the functional consequences of drugs and
molecules [2,3]. However, these molecular assays often use
artificial systems and fluorescent and luminescent molecules, and
are limited to a predetermined mechanism of action (MoA) by
measuring a single signaling molecular species one at a time [4,5].
Label-free cellular assays including dynamic mass redistribution
(DMR) assays enabled by optical biosensors have emerging an
attractive alternative to delineate receptor biology and drug
pharmacology at the whole level [6–10]. Label-free assays are non-
invasive with high sensitivity, so it is possible to investigate the
vectorial behaviors of receptors and molecules including fluores-
cent and luminescent molecules in native cells. Further, label-free
assays offer an integrated functional cellular response, so it is
possible to cover a diverse range of pathways downstream a
receptor [11], and to detect ligands of diverse MoAs for a target
receptor [12].
Firefly luciferin or D-luciferin ((S)-2-(69-hydroxy-29-benzothia-
zolyl)thiazoline-4-carboxylic acid) (Fig. 1) belongs to a class of
light-emitting molecules utilized by a luciferase or photoprotein in
the cells of various bioluminescent organisms [13]. D-luciferin is
the natural substrate of luciferase responsible for the characteristic
yellow light emission from fireflies. D-luciferase catalyzes a
bioluminescence reaction that uses luciferin, Mg-ATP and
molecular oxygen to produce an electronically excited oxyluciferin
species, emitting light with a broad emission spectrum and a peak
at <560 nm yellow-green light [14]. Given the high quantum
yield of the luciferin-luciferase reaction [15] and the change in
bioluminescence color caused by subtle structural differences in
luciferase [16], D-luciferin has been widely used as a substrate to
monitor luciferase activity for in vitro assays and an optical imaging
agent for in vivo imaging [17]. Thus, we were interested in
examining the pharmacological activity of D-luciferin. Here we
applied DMR assays to characterize the activity of D-luciferin in
native human colon adenocarcinoma grade II cell line HT-29, and
found that D-luciferin is a partial agonist of G protein-coupled
receptor (GPCR)-35 (GPR35), a poorly characterized orphan
GPCR.
Results
We used four different types of assays to ascertain the agonist
activity of D-luciferin at GPR35. First, multiple DMR assays were
employed to characterize the pharmacology of D-luciferin in HT-
29 cells, a native cell line endogenously expressing GPR35 [18].
DMR agonist assay was first used to detect the DMR signal
induced by D-luciferin. DMR antagonist assay was then used to
determine the specificity of the D-luciferin-induced DMR to the
activation of endogenous GPR35 using SPB05142, a known
GPR35 antagonist with moderate potency [19,20]. DMR
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of GPR35 to the repeated stimulation with known GPR35 agonists
after D-luciferin treatment. DMR co-stimulation assay was finally
used to determine the competitive agonism of D-luciferin with
pamoic acid, a known GPR35 agonist [20]. Second, D-luciferin-
induced internalization of endogenous GPR35 in HT-29 cells was
examined. Third, D-luciferin-induced ERK phosphorylation in
the absence and presence of GPR35 antagonists was examined in
HT-29 cells. Fourth, Tango b-arrestin translocation assay was
finally employed to examine the agonism of D-luciferin to cause b-
arrestin translocation in an engineered cell line.
D-luciferin triggered a robust DMR signal in HT-29
We first characterized the activity of D-luciferin in HT-29 using
DMR agonism assay, which directly measure its agonist activity.
Results showed that D-luciferin led to a dose-dependent and
saturable DMR signal (Fig. 2a). Its DMR is biphasic, consisting of
an early positive DMR (P-DMR) event and a late negative-DMR
(N-DMR) event. The N-DMR event eventually decays back to a
steady elevated level, compared to the baseline. Based on its P-
DMR amplitude, the D-luciferin DMR dose-response fitted well
with a monophasic sigmoidal curve, leading to an EC50 of
12.961.5 mM (2 independent measurements, each in duplicate,
n=4). Furthermore, titration of D-luciferin up to 128 mM in the
absence of cells showed that it led to a negligible DMR signal,
suggesting that the D-luciferin-induced DMR in HT-29 cells is
specific to the cellular response.
Our recent studies using DMR phenotypic profiling have
led to discovery of novel GPR35 agonists including tyrphostin
analogs [18], 2-(4-methylfuran-2(5H)-ylidene)-malononitrile and
thieno[3,2-b]thiophene-2-carboxylic acid derivatives including
YE210 [19]. We also found that the negative charge groups such
as carboxylic acid and malononitriles appear to be essential to
activate endogenous GPR35 in HT-29 cells [19]. Since D-luciferin
also consists of a thiazoline-4-carboxylic acid moiety and its DMR
characteristics are similar to those induced by the known GPR35
agonists including zaprinast [18] and pamoic acid (Fig. 2b), we
speculated that D-luciferin is a novel agonist for GPR35.
Comparing to the DMR of D-luciferin, both zaprinast and
pamoic acid gave rise to higher potency with an EC50 rank order
of pamoic acid (2.460.4 nM, n=4),zaprinast (162.169.7 nM,
n=4),D-luciferin, as well as higher efficacy based on their
maximal P-DMR amplitude with an rank order of pamoic acid
(274611 pm, picometer in shift of the resonant wavelength),za-
prinast (276617 pm).D-luciferin (198612 pm) (n=36) (Fig. 2c).
These results suggest that D-luciferin is a partial agonist with a
relatively low potency for GPR35.
Figure 1. Chemical structures of GPR35 ligands. The ligands
studied are D-luciferin, zaprinast, pamoic acid, SPB05140, SPB05142 and
SPB05143.
doi:10.1371/journal.pone.0034934.g001
Figure 2. DMR characteristics of ligands in HT-29 cells. (a) The
dose-dependent kinetic DMR signals induced by D-luciferin; (b) the
dose-dependent kinetic DMR signals induced by pamoic acid; and (c)
the P-DMR amplitudes of three ligands as a function of ligand dose. All
data represent mean 6 s.d. from 2 independent measurements, each in
duplicate (n=4), except for zaprinast (n=8).
doi:10.1371/journal.pone.0034934.g002
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activate GPR35
Next, we examined the specificity of D-luciferin to GPR35.
First, we performed DMR desensitization assay, where the cells
were pre-stimulated with D-luciferin at different doses for 1 hr,
followed by repeated stimulation with zaprinast at a fixed dose.
Results showed that D-luciferin dose-dependently caused HT-29
cells desensitized to the repeated stimulation with 250 nM
zaprinast, leading to an apparent IC50 of 6.860.7 mM( 2
independent measurements, each in duplicate, n=4) (Fig. 3),
which was close to the EC50 of D-luciferin to trigger its DMR
signal. This result suggests that both D-luciferin and zaprinast
activate the same receptor, GPR35.
Second, we performed DMR antagonism assay, where the cells
were pre-stimulated with a known GPR35 antagonist at different
doses for 5 min, followed by the stimulation with D-luciferin at a
fixed dose. Previously we had showed that the known GPR35
antagonist CID2745687 (SPB05142; methyl-5-[(tert-butylcarba-
mothioylhydrazinylidene)-methyl]-1-(2,4-difluorophenyl)-pyrazole-4-
carboxylate) (Fig. 1)u pt o6 4mM did not lead to any detectable
DMR in HT-29 cells, but almost completely blocked the DMR
induced by zaprinast [19]. Its two analogs, SPB05140 and SPB05143,
up to 64 mM also triggered little response in HT-29. However, all
three compounds dose-dependentlyblocked the DMRinduced by D-
luciferin at 32 mM( Fig. 4a); and their apparent IC50 values were
5.060.9 mM, 1.560.2 mM, and 2.660.3 mM for SPB05140,
SPB05142 and SPB05143, respectively (2 independent measure-
ments, each in duplicate, n=4) (Fig. 4b). It is worthy noting that the
presence of SPB05142 at the two highest doses examined (16 and
32 mM) converted the D-luciferin DMR to a small but detectable
negative DMR signal, suggesting that D-luciferin may also activate
another cellular target beside GPR35. Nonetheless, these results
suggest that all three compounds are antagonists for GPR35, and D-
luciferin is a GPR35 agonist.
Third, we performed DMR co-stimulation assays, where
concentration-response curves to pamoic acid were performed in
the presence of different fixed doses of D-luciferin; vice versa, the
dose response curves to luciferin were done in the presence of
different fixed doses of pamoic acid. The presence of D-luciferin at
different fixed doses did not alter the potency of pamoic acid, but
increased the starting signal in a dose-dependent manner.
Furthermore, pamoic acid still resulted in an increased signal in
a dose-dependent fashion when D-luciferin up to its saturating
dose (50 mM) was presented, and its maximal responses remained
the same level as the highest dose of pamoic acid in the absence of
D-luciferin (Fig. 5a). Conversely, for low doses of pamoic acid (2
and 20 nM), D-luciferin dose-dependently led to an increased
DMR signal; however, for pamoic acid at 200 nM (a saturating
concentration), high doses of D-luciferin reduced the DMR in a
dose-dependent manner (Fig. 5b). Furthermore, the maximal
responses of pamoic acid in the presence of D-luciferin at all three
doses reached the same level as the highest concentrations of D-
luciferin in the absence of pamoic acid. These results are best
explained by different efficacy of the two compounds interacting at
an overlapping binding site, and D-luciferin is less efficacious
agonist of GPR35 than pamoic acid. Taken together, these DMR
assays suggest that D-luciferin is a partial agonist for GPR35.
D-Luciferin is a partial agonist of GPR35
Since ligand-directed functional selectivity or biased agonism is
quite common to many, if not all, GPCRs [21], we next examined
the activity of D-luciferin using ERK phosphorylation, receptor
internalization and Tango b-arrestin translocation assays. ERK
phosphorylation is a hallmark of the activation and signaling of
many GPCRs including GPR35 [20]. Results showed that
stimulation of HT-29 cells with D-luciferin led to phosphorylation
of ERK in a time-dependent manner, and the maximum ERK
phosphorylation was observed 2 min after stimulation (Fig. 6a).
As controls, the two known GPR35 agonists YE210 and zaprinast
also led to ERK phosphorylation, but pamoic acid led to much
lower ERK phosphorylation (Fig. 6b). The two GPR35
antagonists, SPB05142 and ML145 [22], dose-dependently
attenuated the D-luciferin-induced ERK phosphorylation
(Fig. 6c and d). At the high dose (25 mM) examined,
SPB05142 alone led to a weak but detectable ERK phosphory-
lation via an unknown mechanism. These results suggest that D-
luciferin resulted in ERK phosphorylation via the activation of
GPR35.
Tango
TM GPR35 b-arrestin assay showed that zaprinast led to
a dose dependent response in Tango
TM GPR35-bla U2OS cells
with an EC50 of 5.060.4 mM (2 independent measurement, each
in duplicate, n=4) (Fig. 7a). Similarly, pamoic acid was also
active in this assay with an EC50 of 9.460.7 mM but a lower
Figure 3. The desensitization of HT-29 to 250 nM zaprinast after 1 hr pretreatment with D-luciferin at different doses. Only the
zaprinast-induced DMR signals were shown: (a) the real time kinetic response of zaprinast; and (b) the zaprinast P-DMR amplitudes as a function of D-
luciferin concentration. All data represent mean 6 s.d. from 2 independent measurements, each in duplicate (n=4).
doi:10.1371/journal.pone.0034934.g003
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Compared to DMR assays, Tango b-arrestin translocation assay
resulted in an obvious right-shift in potency, and such a shift was
more significant for pamoic acid (,3800 fold) than zaprinast (,37
fold). Similarly, D-luciferin also triggered clear b-arrestin translo-
cation signal with a relatively low potency (EC50, 277625 mM; 2
independent measurements, n=4), and low efficacy, as evidenced
by that its maximal response was only 20% of the zaprinast
maximal response (Fig. 7a). In a Tango co-stimulation assay the
presence of 100 mM D-luciferin only slightly suppressed the
maximal response of zaprinast; however, the presence of 1 mM D-
luciferin not only increased the starting signal but also suppressed
the maximal response of zaprinast (Fig. 7b). Further, the presence
of D-luciferin at the two different doses had little impact on the
potency of zaprinast. Furthermore, in an alternative Tango co-
stimulation assay wherein zaprinast was fixed at 10 mM, a dose
close to its EC80, D-luciferin triggered a bi-phasic dose response –
it initially increased the Tango response, but at high doses it
started to suppress the zaprinast responses (Fig. 7c). These results
were best explained by that zaprinast is a full agonist of GPR35,
D-luciferin is a partial agonist competitive to zaprinast but with
much lower potency.
Finally, receptor internalization assays showed that similar to
zaprinast and tyrphostin-51 [18], D-luciferin resulted in remarked
internalization of endogenous GPR35 in HT-29 cells (Fig. 8).
Together, these results further strengthen our conclusions; that is,
D-luciferin is a partial agonist for GPR35.
Discussion
Fluorescent and luminescent probe molecules have been widely
used as a substrate or a label for both in vitro molecular assays and
in vivo biomedical imaging. However, little is known for their
activity in cells and tissues. This is partly due to the relatively low
sensitivity and single endpoint measurements of conventional
assays, and partly due to the interference of these labels with the
measurements themselves. Together with their insensitivity to
colors of ligands, the wide pathway coverage makes label-free
cellular assays an attractive means to detect many different classes
of ligands, each having their own biased agonism, for a given
target. D-luciferin is one of the most widely used bioluminescent
substrates in measuring a myriad of biological functions. Here we
Figure 4. The blockage of the D-luciferin-induced DMR by three GPR35 antagonists. Only the D-luciferin DMR signals were shown: (a) the
real time kinetic response of D-luciferin; and (b) the D-luciferin P-DMR amplitudes as a function of GPR35 antagonist concentration. The three GPR35
antagonists were SPB05140, SPB05142 and SPB05143. All data represent mean 6 s.d. from 2 independent measurements, each in duplicate (n=4).
doi:10.1371/journal.pone.0034934.g004
Figure 5. The DMR arising from co-stimulation with two agonists. (a) The dose-dependent responses of pamoic acid in the absence and
presence of D-luciferin at three different fixed doses; the cell seeding density was 25000 cells per well; and (b) the dose-dependent response of D-
luciferin in the absence and presence of pamoic acid at three fixed doses, the cell seeding density was 32000 cells per well. The ligand P-DMR
amplitudes were used to calculate all dose responses. All data represent mean 6 s.d. from 2 independent measurements, each in duplicate (n=4).
doi:10.1371/journal.pone.0034934.g005
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D-luciferin, and discovered a previously unknown activity of D-
luciferin; that is, D-luciferin is a partial agonist of GPR35.
GPR35 is an orphan GPCR, and has been implicated in
hypertension [23], coronary artery disease [24], asthma [25], pain
[26], inflammation [27], and cancers [28]. Several different classes
of molecules have been discovered to modulate GPR35 activity
[18,19,21,29–33]. These GPR35 ligands exhibit quite diversity in
chemical scaffold, making one speculate the mostly unknown
biology and pathophysiology of GPR35 [34]. Nonetheless, the
discovery of D-luciferin to be a partial agonist of GPR35 has
added a novel chemical class to the increasing list of pharmaco-
logical tools available for probing the biology and pathophysiology
of GPR35. Furthermore, we found that the potency of D-luciferin
to activate GPR35 in native HT-29 is comparable to it Km value
(16 mM) binding to purified luciferase enzyme [13]. Considering
that the doses used for in vitro assays and in vivo imaging are often
much higher that its Km [13], the GPR35 agonist activity of D-
luciferin observed here will call close examination of the
pharmacological activity of fluorescent and luminescent probe
molecules widely used in conventional assays, and also evoke
careful interpretation of biological data when these molecules are
used.
Figure 6. D-Luciferin triggered ERK phosphorylation via
GPR35. (a) Western blot of phosphorylated ERK1/2 (pERK1/2) after
treated with 32 mM D-luciferin for different times; (b) Western blot of
phosphorylated ERK 30 min after treated with three different known
GPR35 agonists, YE210 (1 mM), zaprinast (1 mM) and pamoic acid (1 mM);
(c) Western blot of phosphorylated ERK 5 min after treated with 32 mM
in the presence of SPB05142 at different doses; (d) Western blot of
phosphorylated ERK 5 min after treated with 32 mM in the presence of
ML145 at different doses. The phosphorylated ERK and total ERK were
blotted, and actin was used as control. Representative images obtained
from 2 independent measurements were used.
doi:10.1371/journal.pone.0034934.g006
Figure 7. D-Luciferin caused b-arrestin translocation via GPR35. (a) The dose-dependent responses of three ligands as measured using
Tango
TM b-arrestin translocation gene reporter assays. (b) The dose-dependent responses of zaprinast in the presence of D-luciferin at different fixed
doses. (c) The dose-dependent responses of D-luciferin in the presence of 10 mM zaprinast. All data were normalized to the zaprinast maximal
response. The data represents mean 6 s.d. from two independent measurements, each in duplicate (n=4).
doi:10.1371/journal.pone.0034934.g007
Figure 8. D-Luciferin triggered internalization of endogenous
GPR35 in HT-29 cells. Representative confocal fluorescence images
of HT-29 under different conditions: (a) treated with the assay vehicle
containing 0.1% DMSO; (b) treated with 32 mM D-luciferin. The images
were obtained after compound treatment for 1 hr, permeabilized,
stained with anti-GPR35, followed by fluorescent secondary antibody.
Red: GPR35 stains. Representative images obtained from 2 independent
measurements were used.
doi:10.1371/journal.pone.0034934.g008
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Materials and cells
Pamoic acid and D-luciferin were obtained from Sigma
Chemical Co. (St. Louis, MO, USA). ML145 was obtained from
Tocris Chemical Co. (St. Louis, MO, USA). Zaprinast was
purchased from Enzo Life Sciences (Plymouth Meeting, PA).
SP05140, SPB05142 and SPB05143 were obtained from Ryan
Scientific, Inc. (Mt. Pleasant, SC). YE210 [19] and EpicH 384-well
biosensor microplates were obtained from Corning Inc. (Corning,
NY). Mouse monoclonal anti-phosphorylated extracellular-signal-
regulated kinase 1/2 (anti-pERK1/2) (Cat#M9682) and mouse
monoclonal anti-ERK1/2 (#M7431) were obtained from Sigma.
HT-29 was obtained from American Type Cell Culture
(Manassas, VA). The cells were cultured in McCoy’s 5a Medium
Modified supplemented with 10% fetal bovine serum, 4.5 g/liter
glucose, 2 mM glutamine, and antibiotics at 37uC under air/5%
CO2. Tango
TM GPR35-bla U2OS cells were purchased from
Invitrogen (Grand Island, NY). Tango
TM GPR35-bla U2OS cells
stably expresses human GPR35 linked to a TEV protease site and
a Gal4-VP16 transcription factor, as well as a b-arrestin/TEV
protease fusion protein and the b-lactamase reporter gene under
the control of a UAS response element. The cells were cultured
according to the protocols recommended by the supplier. Briefly,
the cells were passed using McCoy’s 5A medium (Invitrogen,
Cat#16600-082) supplemented with 10% dialyzed fetal bovine
serum, 0.1 mM NEAA, 25 mM Hepes (pH 7.3), 1 mM sodium
pyruvate, 100 U/ml penicillin, 100 mg/ml streptomycin, 200 mg/
ml zeocin, 50 mg/ml hygromycin, and 100 mg/ml geneticin in a
humidified 37uC/5% CO2 incubator.
Dynamic mass redistribution assays
All DMR assays [35] were performed using EpicH system
(Corning Inc.). EpicH is a wavelength interrogation reader system
tailored for resonant waveguide grating biosensors in microtiter
plates. This system consists of a temperature-control unit (26uC),
an optical detection unit, and an on-board liquid handling unit
with robotics. The detection unit is centered on integrated fiber
optics, and enables kinetic measures of cellular responses with a
time interval of ,15 sec. Cells were directly seeded in EpicH plates
and cultured overnight to form confluent monolayer in the cell
culture medium. The cell seeding density was 32, 000 cells per
well, unless specifically mentioned. After being washed twice, the
cells were maintained with HBSS (16Hanks balanced salte buffer,
10 mM Hepes-KOH, pH 7.1) and further incubated inside the
system for 1 hr. After a 2-min baseline, the agonism profiles of
ligands in the absence and presence of another compound at a
fixed dose were recorded immediately after the ligand additions,
while the antagonism or desensitization profiles were indicated by
the DMR of a ligand at its EC50 or EC100 after the cells were
pretreated with a compound or an agonist, respectively, for 1 hr.
The assay vehicle containing equal amount of DMSO (dimethyl
sulfoxide) was used as a control. All ligand-induced DMR were
background corrected. All EC50 or IC50 reported were calculated
based on the amplitudes of DMR signals at 8 min post agonist
stimulation, unless specifically mentioned.
ERK MAPK assays
The p44/42 MAP kinases were examined using Western
blotting. Whole cell lysates were collected after the cells were
treated with a compound or DMSO for 1 hr. Equivalent gel
loading was confirmed by probing with anti-actin body. The total
ERK1/2 and phosphorylated ERK1/2 were blotted using
respective antibodies.
Tango
TM b-arrestin assays
Tango
TM GPR35 b-arrestin assay utilizes GPR35 agonist-
induced recruitment of protease tagged b-arrestin to GPR35 that
has been modified at the C-terminus to include a transcription
factor linked by a protease cleavage site. As a result of arrestin
recruitment, the protease cleaves the transcription factor from the
receptor, which then translocates to the nucleus and activates the
expression of b-lactamase. The assay protocol recommended by
the supplier was used. Briefly, 10000 cells per well were seeded in
384-well, black-wall, clear bottom assay plates with low fluores-
cence background (Corning), and cultured in DMEM (Invitrogen,
10569-010) supplemented with 10% dialyzed fetal bovine serum,
0.1 mM NEAA, 25 mM Hepes (pH 7.3), 100 U/ml Penicillin, and
100 mg/ml Streptomycin. After overnight culture, the cells were
stimulated with ligands for 5 hrs in a humidified 37uC/5% CO2,
and then loaded with the cell permeable LiveBLAzer
TM FRET B/
G substrate. After the two hour incubation the coumarin:fluor-
escein ratio in the presence of a ligand was measured using Tecan
Safire II microplate reader (Ma ¨nnedorf, Switzerland). All results
obtained were normalized to the zaprinast maximal responses
using an intra-plate referencing protocol; that is, a dose response of
zaprinast was obtained within the same plate, and a compound
response was then normalized to the maximal response of
zaprinast which was set to be 100%.
Receptor internalization
HT-29 cells were plated on an 8-well chamber slide (Nalge
Nunc International, Rochester, NY, USA) with a seeding density
of 10,000 cells per well and incubated at 37uC for 24 hrs. Next
day, cells were stimulated with a compound or equal amount of
DMSO at 37uC for 1 hr. Afterwards, cells were fixed with 4%
formaldehyde in 16PBS for 15 min, followed by blocking and
permeabilization in a buffer containing 4% goat serum, 0.1%
bovine serum albumin (BSA), 0.1% Triton 6100 in 16PBS for
2 hrs. After 5 min wash with PBS, fixed cells were incubated with
the anti-GPR35 (1:500) (anti-GPR35, T-14, intracellular domain)
(Santa Cruz biotechnology, Santa Cruz, CA, USA) in 3% BSA/
PBS buffer for 24 hrs, followed by incubation with secondary
antibody Alexa FluorH 594 donkey anti-goat IgG (H+L) (1:500)
(Invitrogen) in 3% BSA/PBS for 1 hr at room temperature. Cells
were finally washed once with PBS and sealed with 1.5 mm thick
glass cover-slip (Corning, NY). Dried slides were stored at 4uC
until imaging. Confocal imaging was performed with Zeiss
confocal microscope Axiovert 40. The specificity of anti-GPR35
was confirmed by the control peptide from the supplier. Staining
showed that the control peptide completely blocked the staining of
HT-29 cells with the anti-GPR35 antibody. The collected images
were analyzed using MacBiophotonics Image J software (http://
www.macbiophotonics.ca/downloads.htm).
Statistical analysis
For dose responses, at least two independent measurements,
each done at least in duplicate, were performed to calculate the
mean responses and the standard deviations (s.d.).
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